Longboard Pharmaceuticals, Inc. financial data

Symbol
LBPH on Nasdaq
Industry
Pharmaceutical Preparations
Location
4275 Executive Square, Suite 950, La Jolla, California
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 2, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.43K % +42.7%
Return On Equity -49.9 % +21.4%
Return On Assets -46 % +19.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36M shares +56.8%
Common Stock, Shares, Outstanding 33.6M shares +63.6%
Entity Public Float 148M USD +185%
Common Stock, Value, Issued 3K USD +50%
Weighted Average Number of Shares Outstanding, Basic 35.3M shares +73.1%
Weighted Average Number of Shares Outstanding, Diluted 35.3M shares +73.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 48.4M USD +34.2%
General and Administrative Expense 14.5M USD +30.8%
Operating Income (Loss) -62.9M USD -33.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -58M USD -26.5%
Earnings Per Share, Basic -2.25 USD/shares +12.1%
Earnings Per Share, Diluted -2.25 USD/shares +12.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 54.4M USD +117%
Cash, Cash Equivalents, and Short-term Investments 321M USD +322%
Assets, Current 323M USD +310%
Other Long-term Investments 244K USD +597%
Property, Plant and Equipment, Net 3K USD -62.5%
Operating Lease, Right-of-Use Asset 3.98M USD +484%
Assets 328M USD +311%
Accounts Payable, Current 1.05M USD +269%
Accrued Liabilities, Current 572K USD -46.4%
Liabilities, Current 10.3M USD +42.1%
Operating Lease, Liability, Noncurrent 3.67M USD +1075%
Accumulated Other Comprehensive Income (Loss), Net of Tax -366K USD +13.1%
Retained Earnings (Accumulated Deficit) -156M USD -59.4%
Stockholders' Equity Attributable to Parent 314M USD +335%
Liabilities and Equity 328M USD +311%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.2M USD -15.9%
Net Cash Provided by (Used in) Financing Activities 286M USD +1241%
Net Cash Provided by (Used in) Investing Activities -231M USD -3896%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 33.6M shares +63.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 40.3M USD +181%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 54.6M USD +118%
Deferred Tax Assets, Valuation Allowance 31M USD +70%
Cash and Cash Equivalents, Period Increase (Decrease) -31.3M USD -148%
Deferred Tax Assets, Gross 31.1M USD +69.1%
Operating Lease, Liability 3.98M USD +483%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -57.9M USD -26.9%
Lessee, Operating Lease, Liability, to be Paid 5.36M USD +639%
Operating Lease, Liability, Current 315K USD -15.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 785K USD +83.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 663K USD +122%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.38M USD +3109%
Lessee, Operating Lease, Liability, to be Paid, Year Three 820K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.15M USD +63%
Lessee, Operating Lease, Liability, to be Paid, Year Four 856K USD
Operating Lease, Payments 105K USD +11.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 31M USD +70%
Share-based Payment Arrangement, Expense 4.31M USD +54.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%